CHARITY NO: 1203103
The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
IMPACT
REPORT
2025/26
ri()
Learn more about our work at
humaneresearch.org.uk

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
CONTENTS
ri
ABOUT
About
04
Foreword from the Chair
and CEO
05
Strategic Objectives
2023-26
08
OUR IMPACT
2025-26
Our impact
09
Anlmal-free research
grant programme
10
Promotlng the eff5cacy
of anlmal-free research
25
New grants awarded
10
Engagement events
25
Fellowship award
1S
Our work featured in Nature
26
2026 funding round
16
Replacing animals in science
27
Ongoing research
17
Thank yous
28
Grant withdrawal
17
Environmental. social
and governance strategy
32
Grants completed
18
Published THRT
research
24
Independent scientif ic
advisory panel
24

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
GOVERNANCE AND
FINANCIALS
Our governance framework
33
Statement of the Trustees.
responsibilities
45
Charitable objects
34
Independent auditor's report
46
Future plans
34
Audited accounts
52
Appointment and training
of Trustees
35
Risk and incident managemernt
36
Investment powers and objectives
37
Pu blic benefit
37
Grant-making policy
38
Our people
39
Reference and administrative
details
40
Fi nancial position
41
Investments
43
Reserves policy
44

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
ABOUT
The Humane Research Trust is dedicated to advancing life-saving medical research
without the use of animals.
Since 1961, we have funded pioneering scientists developing innovative, human-relevant
research methods that are more ethical, more reliable, and better able to predict human
disease.
According to the UK Government's latest statistics. 2.54 million scientific procedures
involving living animals were carried out in Great Britain in 2025. While this represents
the lowest total recorded under the Animals (Scientific Procedures) Act 1986. more than
1.3 million procedures were conducted for experimental research, with 95% involving
mice, f ish, birds or rats.
Over half of these experimental procedures supported basic research. and almost half
of all procedures involved the creation and breeding of genetically altered animals for
future research,
Research on animals in UK labs
decreased by 3.80A in 2025
S Million
4 mlmion
3 mlllson
2 mllllon
2007
202S

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
FOREWORD FROM CHAIR
AND CEO
We are delighted to present The Humane Research Trust's Impact Report and Financial
Statements for the period l April 2025 to 31 March 2026. This has been a year of
significant progress for the Trust and for the wider animal-free research sector.
ee
Demand for our funding reached unprecedented levels,
demonstrating both the growing scientific interest in human-
relevant research methods and the increasing recognition that
animal-free approaches can deliver robust. Innovative solutions
to some of the most pressing challenges in medical science.
Our 2025 funding round l attracted a record 34
applications with a combined value of £5.8 million.
2025-26 Highlights
34
Following rigorous independent peer review, we
were pleased to award four new grants across a
diverse range of disciplines, from respiratory
infection and cancer immunotherapy to age-
related eye disease. Together. these projects have
the potential to accelerate scierntific discovery
while reducing reliance on animals in research.
Appllcatlons recelved
New grants awarded
£624K
Combinèd value
Beyond new grant awards. we continued to
support 22 active research projects at universities
cross the United Kingdom, with more than £2 3
million committed to ongoing research at the end
of the reporting period.
23
Active r•s8arch
projects supportèd
These investments reflect our long-term commitment to nurturing
scientific excellence and enabling researchers to develop
innovative, reproducible and human-relevant methods that can
transform biomedical research.

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
We were also pleased to strengthen our collaborative approach through a new
partnership with the Naturewatch Foundation to support the next Humane Research
Trust Fellow. By combining expertise and resources. we can increase our impact and
help develop the next generation of scientists dedicated to advancing animal-free
research.
ee
Together, we are helping to build a future in which medical
research is more humane, more relevant to human biology, and
more effective In delivering benefits for patients.
During the year, trustees also reviewed how environmental. social and governance
considerations are embedded within the Trust's activities and decision-making As a
charity committed to creating positive change, we recognise the importance of
operating responsibly and sustainably. ensuring that our values are reflected not only in
the research we fund but in the way we conduct our work.
None of these achievements would be possible without the generosity of our
supporters, the dedication of our researchers. the commitment of our Scientific
Advisory Panel, and the contribution of our staff and trustees. We extend our sincere
thanks to everyone who shares our vision of a future where advances in medicine are
achieved without the use of animals.
This year we said goodbye to Bryan Homan. a trustee and chair of the board's science
sub-committee. We are immensely grateful for his time and valuable contribution to the
science programme, which developed significantly under his guidance.
We also said goodbye to Professor Aline Miller, a trustee and member of the board's
science sub-committee. We thank Aline for her expertise and for the opportunity she
afforded us to host our symposium at University of Manchester.

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
.As we look ahead. we remain ambitious. In 2026 we will launch a new funding
call focused on research into neurological conditions and the microbiome,
selected by our supporters.
We will continue to expand our grant programme. champion the effectivèness of
animal-free methods. and raise awareness of the opportunities these approaches
offer for both science and society.
Janet Tate-smith
Chair of Trustees
Dr Alison Glles
Chief Executive Officer

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
STRATEGIC OBJECTIVES 2023-26
The Trust's strategy for 2023-26 sets out
three objectives towards achieving its mission:
st￿ngthen and
expand our animal-
free research grant
programme.
Promote the efflcicy
of anlmal-free
research
Prtynot¢ the Trust's
sion and mission to
the wbli
The strategy is underpinned by activities to ensure the Trust remains a
sustainable and resilient organisation with sufficient skills, support,
and income to deliver its objectives.

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
OUR IMPACT 2025-26
This year. your support helped..
Fund innovative animal-free research across respiratory disease,
cancer. eye disease and infection
Support projects with the potential to replace the use of more than
166,000 mice every year
Advance human-relevant technologies including organ-on-chip
systems, human tissue models and advanced cell culture platforms
Contribute to research published in leading scientif ic journals.
including Nature and npj Parkinson's Disease

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Objective I:
Animal-free research grant
programme
To accelerate progress towards our mission, we seek to engage with more Institutions,
diversify the institutions we fund. and increase the amount of funding awarded. The
Trust's funding must be used to replace animals in research, and the priority is the
development of novel methods that are reproducible.
New grants awarded
The 2025 Funding Round I closed on 23 February 2025. A record 34 applications were
submitted, with a total value of É5.8m. Following peer review by members of our
independent scientific advisory panel. four new grants were awarded in August 2025,
with a total commitment of £624.027.
Read about the grants
10

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Dr Margherita Bertuzzi, University of Manchester
Development of a next-generation animal-free microfluidic technology to understand
antimicrobial immunity against lethal respiratory pathogens in the lungs.
Respiratory infections are the fourth leading cause of death worldwide. Among these,
fungal infections pose a growing threat. Inhalation of spores fromAspergillus
fumigatus- a major mould pathogen
causes over 3 million chronic and invasive
d iseases annually, resulting in 1.5 million deaths every year.
Dr Bertuzzi's team will develop a microfluidic 'lung-on-a-chip platform a miniature,
artificial lung environment that mimics the structure and function of human
alveoli. Using this platform. the team will study how the alveolar epithelium recognises
and kills Aspergillus fumigatus and how these processes influence immune responses,
They will also investigate what goes wrong in Chronic Obstructive Pulmonary Disease,
where epithelial dysfunction increases susceptibility to fungal infections.
The team estimates their model will immediately replace a minimum of 200 mice
yearly and wider use of their model will lead to further replacement of at least 2,000
mice in the next 5 years.
14n
Dr Margherita Bertuzzi
(Principal Investigator)
Keira Gordon
(PhD student)

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Dr Raymond Allan, De Montfort University
Development of a humane respiratory epithelial model for
pneumococcal infection
Pneumonia remains one of the world's deadliest infectious diseases. claiming millions
of lives each year. Among its leading culprits is Streptococcus pneumoniae, a
bacterium that resides harmlessly in the upper respiratory tract, but under certain
conditions shifts to an invasive state. causing severe infection.
Dr Allan's team is developing a novel respiratory epithelial model that supports long-
term infection under conditions that mimic the human airway.
Using small airway epithelial cells grown at an air-liquid interface, the model will
reproduce key features of the respiratory tract. including mucus production and the
formation of cilia (hairlike structures that help cells communicate)
This novel model will offer an attractive. low-cost alternative that can replace animals
(mice, chinchillas, rabbits, rats) that are commonly used for treatment screening,
cytotoxicity testing, and exploring the mechanisms of pathogenesis.
Dr Raymond Allan
(Principal Investigator)
Divine Derefaka
(PhD student)
12

The Humane
Research Trust CIO
Helping people, Saving anirnals
Dr Nick Peake, Sheff ield Hallam University
Repurposing surgical waste tissue to develop humanised models for cancer
immunotherapy testing Cbowel cancer)
Bowel cancer is the third most common cancer worldwide and the second leading cause
of cancer-related deaths in the UK. Despite advances in surgery and chemotherapy, up to
50Yo of patients experience disease recurrence. highlighting the urgent need for better
therapies.
Immunotherapy treatments that retrain the patient's own immune system to attack
cancer cells - offers enormous promise. However. only 15-20% of bowel cancer patients
respond to current immunotherapies. This low success rate is largely due to the
complexity of the tumour microenvironment which blocks immune cells from reaching
tumours and allow cancer cells to evade detection.
Dr Peake's team is repurposing surgical waste tissue and blood samples from bowel
cancer patients to create fully humanised. immunocompetent models that accurately
replicate the tumour microenvironment. This means they can observe how a patient's
immune system responds to their cancer cells. and how the tissue structure acts as a
barrier to cancer immunotherapy.
y developing a platform based on human tissue and cells. this project could help to
reduce reliance on up to165,000 mice used annually in UK cancer research.
The research will start in the next financial period.
Dr Nick Peake
(Principal Investigator)
Dr Rhianna Blyth
(Research fellow)
13

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Dr Yifan Li. Northumbria University
(BIRDIE) Biomimetic In-vitro Research with tuneable Deforming surfaces Induced by
Elastomer-hydrogel System (age-related eye disease)
Eye diseases such as age-related macular degeneration (AMD) and other retinal
disorders affect millions worldwide. AMD is one of the leading causes of vision loss in
older adults It gradually destroys the cells that support the retina and disrupts the
delicate balance of mechanical and biochemical signals that keep the eye healthy,
To develop better therapies, scientists need models that replicate both healthy and
diseased states of the human eye. That means mimicking not only the chemical
environment but also the physical changes that occur as disease advances.
Dr Li's team will build a revolutionary platform that replicates the living retina more
closely than ever before. Instead of static surfaces, the system will use soft elastomers
and hydrogels engineered to bend, stretch, and wrinkle, just like real eye tissue, This
means scientists can study how healthy cells behave and how disease begins under
conditions that truly reflect human biology.
The research will start in the next funding period.
Dr Yifan Li
(Principal Investigator)
14

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Fellowship award
Following the successful completion of a
fellowship awarded to Dr Luke Green at
University of Sheffield, which finished in July
2025, we opened a grant-funding round to
identify a new THRT Fellow.
At a glance:
Applications opened..
December 2025
Applications opened in autumn 2025 and
closed on 21 December 2025. A total of 19
Stage l applications were received, in which
applicants were asked to describe their
research career to date and their future career
aspirations, and to outline their research
proposal.
19 Stage 1
applications received
New partnership with
Naturewatch Foundation
The nine applicants whose backgrounds.
aspirations and research proposals most closely
aligned with the intention of the Fellowship
were invited to submit a Stage 2 application.
The Stage 2 applications will be peer-reviewed by members of our independent scientific
advisory panel and a final decision will be taken in May 2026.
We are delighted to partner with Naturewatch Foundation on this award. Naturewatch
Foundation has a long-standing campaign to end animal experiments and was looking to
fund projects to develop alternative methods to animal testing. They approached The
Humane Research Trust to SLJggest a partnership. In recognition of our reputation as an
experienced funder of high-quality research. Their funding contribution will support
public engagement activities by the Fellow.
15

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
2026 Funding round - our next funding priority
In 2025. we launched a supporter survey with a list of five disease areas for them to
choose from for a disease-focused grant call in 2026. The choice was between
autoimmune diseases (joints and muscles).. chronic pain.. neurological conditions and
the microbiome,. sepsis., and women's reproductive health. These areas are all
underserved by animal-free models and cause significant morbidity.
We had a very stron9 response and the disease area with the most votes was
neurological conditions and the microbiome. We will launch the grant round in June
2026, inviting applications from UK-based researchers focused on this area. We will run
a focused fundraising campaign alongside the grant.
Sepsls
16.3%
Chronlc paln
24%
Autoimmune
dlseases (Jolnts
and muscles)
18.8%
Women's
reproductlve
health
9.2%
Neurological
conditions and the
microbiome
31.7%
16

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Ongoing research
During the period, the Trust continued to support 23 F)rojects at the Universities of
Birmingham (2 projects). Sheffield. East Anglia (3 projects). Aberdeen, Nottingham,
Manchester, Reading, Keele. Bristol. Surrey. Oxford. Edinburgh (2 projects), Liverpool
John Moores, University College London (3 projects). Glasgow. Royal Veterinary
College, and Nottingham Trent. A list of all active research grants during the period is
given in Note 7 to the financial statements.
It should be noted that Professor Julie Gough, the principal investigator of a project at
University of Manchester. is also a trustee of the Trust. This is recorded as a related
party transaction in the notes to the financial statements.
As at the end of March 2026, over £2.3m has been committed to ongoing research
projects at UK universities, across 22 projects. The Trust has made grant commitments
until December 2029.
Grant withdrawal
We awarded Dr Olivier Cexus at University of Surrey a grant in February 2025..
Deciphering the cause of autoimmune thyroi.d diseases using human Immune thyroid
organoids.
During the contract finalisation process. Dr Cexus withdrew his application following a
decision to relocate his work outside of the UK. He thanked the Trust for the
opportunity to apply for funding.
17

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Grants completed in the reporting period
General grant
Project: Creating a Systems-level Model of the Neural Mechanisms Underlying
Impaired Impulse Control in Parkinson's Disease
Principal investigators: Dr Craig McAllister, Dr Hayley MacDonald (now at Bergen,
Norway)
Pho student: Aliya Warden
University: University of Birmingham
Impulse control disorders, such as compulsive gambling and binge eating, affect many
eople living with Parkinson's disease. particularly those taking dopamine agonist
medication. Despite their serious impact on quality of life. it has not been clear why
these behaviours develop or how to Identify those most at risk.
We funded a research project at the University of Birmingham to address this gap
using entirely animal-free methods. The researchers worked directly with people to
understand how changes in brain and muscle activity contribute to impaired impulse
control in Parkinson's disease.
The project revealed distinct patterns of brain and muscle activity li nked to diff Iculties
with impulse control in people with Parkinson's disease. Some of these patterns were
associated with more impulsive behaviours in everyday life, and greater disease
rogression.
This research has laid the groundwork for developing objective, human-relevant
markers of impulse control difficulties in Parkinson's disease. In the future, these
measures could help identify people at risk of developing Impulse control disorders
earlier, enabling closer monitoring and more personalised treatment decisions.
18

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
By studying impulse control directly in people, the findings are immediately relevant
to patients and clinicians and help reduce reliance on animal models in Parkinson's
research.
Planned next steps will propose non-invasive brain stimulation as a treatment option
to improve and/or prevent impulse control problems in Parkinson's patients. One key
aim will be to apply a brain stimulation protocol alongside the start of dopamine
medication in a group of early patients to counteract any deficits in impulse control
from the medication.
The PhD student who undertook the research. Aliya Warden. successfully defended
her thesis in September 2025. She has since begun a postdoctoral fellowship in the
Faculty of Electrical Engineering at the Czech Technical University in Prague, where
she is advancing her goal of translating scientific knowledge into improved
treatments for people with neurological conditions. She has joined a team
specialising in neuromodulation techniques. including deep brain stimulation (DBS),
applying her expertise In neural signal analysis In Parkinson's disease to optimise
DBS therapy and enhance clinically meaningful outcomes.
Her research led to 3 peer-reviewed publications.
Aliya Warden (PhD student) and Dr Hayley MacDonald
Dr Craig McAllister (Principal Investigators)
19

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
THRT Les Rhoades memorlal studentshlp
Project: The Cellular and Molecular Basis of Neurodevelopmental Disorders
Principal investigator: Dr Eunchai Kang
PhD student: Do Hyeon Gim
Unlverslty: University of Aberdeen
The human neocortex is the part of the brain responsible for advanced functions like
thinking, memory. language. and decision-making. Understanding how the neocortex
forms is essential for revealing the root caLJses of human-specific brain conditions. These
include neurodevelopmental disorders such as autism and intellectual disability, as well
as psychiatric and degenerative disorders like schizophrenia and Alzheimer's disease
Animal models, particularly
rodents, have long been used in
neurological research. But the
developing human cortex
contains unique neural stem cells
that are absent in other species.
Fibroblasts
Rwowam
I hiPSCS
JO +*ff•rant*t￿n
Brarn organoids
As a result, animal models
are limited in their ability to
replicate hu man-specif ic
neurolog ical d isorders.
Skin biopsy
Dr Kang's team addressed this challenge by using human cell culture systems to grow
three-dimensional structures that replicate the process of human cortical development in
the lab.
Their research focus was on the influence of the extracellular matrix (ECM), a network of
proteins and molecules that surrounds and supports the brain cells.
20

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Do Hyeon Gim, the PhD student. has completed his doctoral thesis and undertook
postdoctoral training at the University of Oxford. In spring 2026 he secured a prestigious
postdoctoral fellowship at University of California. San Francisco.
They Identified that the ECM is unique to each type of brain cell and that It changes
significantly as the brain develops Importantly. they identified 139 genes involved in the
ECM that have been linked previously to neurodevelopmental disorders. This knowledge
provides the opportunity for researchers to focus on how these genes regulate normal
development and could inform new strategies for treating neurodevelopmental
disorders.
The team has secured a further É738K from the Medical Research Council to continue
this work,
The research has led to a publication in Nature Communications and a second paper
currently under revision in Nature Neuroscience, both highly prestigious journals.
IA
Dr Eunchai Kang, Dr Thomas Hiscock (Principal Investlgators)
and Do Hyeon Gim (PhD student) alongside their team
21

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
THRT Fellowshlp
Project tltle: Hijack of the host.. Uncovering how bacteria remodel human cell surface
proteins to promote infection
Fellow and principal investigator: Dr Luke Green
PhD student: Paige Wolverson
Unlverslty: University of Sheffield
Bacterial diseases are a significant health burden globally and the rising resistance of
bacteria to the antibiotics used to treat them is now regarded as a major public health
threat. To develop alternative treatment strategies, we must increase our understanding
of how bacteria are able to get inside human cells. One disease of interest is bacterial
meningitis, where bacteria cross the blood-brain barrier and cause Inflammation In the
brain, which can be fatal.
Traditionally, bacterial infection studies have relied heavily on animal models.
particularly genetically modified mice. Our funding enabled Luke's team to use human
cells to recreate the blood-brain barrier in a 3D model in the lab. They used the model
to study how the bacteria that cause meningitis interact with proteins on a cell's
surface and how this enables them to cross the barrier.
H•althy r•ll surlace
Bact•ilal attaEhm•nt
JlJJ•UI lJ•Jl
IIILJStration showing how Neisseria meningitidis
sticks to human cells U51ng surface molecules.
helping it Cause infection.
22

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Their model revealed that the bacteria induce the cell to release pro-inflammatory
cytokines that increase the permeability of the barrier. Importantly, they were able to
show that a specif ic peptide could signif icantly reduce the bacteria's ability to stick to the
cell's surface and trigger inflammation, suggesting the peptide could be used as a
therapeutic treatment to reduce Infection.
The research led to two peer-reviewed publications.
The PhD student, Paige Wolverson. successfully defended her PhD and now has a
postdoctoral position at Loughborough University working on the blood-brain barrier
during infection.
Our award has enabled Luke Green to move from the position of Research Fellow to his
current position as a Lecturer at the School of Clinical Dentistry in Sheff ield.
L, kli,
.7
Dr Luke Green
(Principal Investlgator)
Paige WolVe￿On
(PhD Student)
23

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Published THRT research
During the reporting period, our funded research featured in the below publications.
Thomas Walne, Laura Maple, Nan Li, Isabel Christie, Carl Smythe. Ruth Thompson. A novel
role for UPFI in safeguarding DNA replication in S phase and beyond. bioRxiv
2025,05.22.655556
Aliya C. M. Warden, Craig J. McAllister. Damian Cruse. Ben Wright & Hayley J. MacDonald.
Muscle bursting and corticomotor excitability mark Impaired impulse control in Parkinson's
disease. npj Parkinson's Disease volume 12. Article number.. 11 (2026)
Aliya C. N. Warden, Damian Cruse, Craig J. McAllister and Hayley J. MacDonald P-bursting
as a sensitive neural marker of inhibitory control In healthy older adults.. a linear mixed-
effects modelling and threshold-free cluster approach. Journal of Neuroscience 24
February 2026, e1151252026, tsLLoL&doLLr
Gim, D, H., Assir, M. Z. K.. Fowler. P. A. F., Morgan, M., Berg, D., Kang, E. Deciphering Cell-
Type and Temporal-specific Matrisome Expression Signatures in Human Cortical
Development and Neurodevelopmental Disorders via scRNA-Seq Neta-Analysis. 2025
Published
14
Judith Madden, Peter Penson. Philippa Mccabe. Alessio Gamba. An updated systematic
review to determine the chemical space of existing physiologically-based kinetic (PBK)
models and to determine most commonly used methods of model evaluation. PROSPERO
2025 CRD420251110775
Independent scientific advisory panel
Members of our independent scientific advisory panel peer-review grant applicatior)s and
are occasionally involved in other activities of the Trust.
We post regularly on Linkedln inviting academics around the world to join the panel
In this reporting period we are pleased that the r)umber of panel members
has increased from 12 to 54, indicating the growing responsibility
academics feel towards the replacement of animals in research.
24

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Objective 2:
Promoting the efficacy of
animal-free research
The Trust advances human-relevant science by promoting effective non-animal research
methods and supporting the development of new alternatives to animal use in medical
research.
Engagement events
We exhibited at the Tissue and Cell Engineering Society conference hosted by the
University of Bristol (18-20 June 2025) and the British Microcirculation & Vascular Biology
Society conference hosted by the University of Surrey (July 2025). These events provided
valuable opportunities to engage with researchers and promote the Trust's mission and
funding programmes.
In December 2025, we attended the LUSH annual
reception at the House of Commons alongside
parliamentarians and NGO representatives.
LU$
PRIZE
As a rrember of the Alliance for Human-Relevant
Science, we participated In a Westminster
showcase on 4 November 2025, hosted by Steve
Pace MP. We were pleased that our local MP for
Che3dle, Tom Morrison, attended in support of the
Trust
As a member of the Alliance for Humar)-Relevant
Science, we participated in a Westminster
ghowcase and a Royal Society Science Plus event.
A Human Focus for 21st Century Life Sciences The
latter attracted 320 delegates from academia,
industry. parliament and regulatory bodies, with a
special issue of Phi losophical Transactions B now in
preparation, exploring key themes from the event.
Our CEO Dr Alison Giles with
THRfpatron Chris Packham CBE
25

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Our work featured in Nature
One action arising from the symposium we held in partnership with University of
Manchester in September 2024 was to send a joint statement to journal editors. Professor
Val Speirs from University of Aberdeen led on this, and two of our trustees, Professor Julie
Gough and Professor Aline Miller were part of the drafting group.
The final piece was published in Nature. "llo￿1
rn
hin
rn
5c%t1n8(IK'wndJinic￿Irch
Comment
Journals, fundersand researchersmust
get behind alternativestoanimal testing
26

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Replacing animals in science: A strategy to support
the development, validation and uptake of
alternative methods
In November 2025. we cautiously welcomed the Government's "R
nim
Lod&" The document focuses on the replacement of very specific animal tests like in
vivo skin irritation testing. Whilst this is good news, many of these tests could have been
outlawed before now.
The Strategy also includes new infrastructure commitments. backed by £60 million to
promote the development of human-relevant models and support the path to regulatory
approval of tests and approaches to replace the use of animals.
Sadly, the strategy does not provide any detail on replacing the use of animals in basic
research. The Trust will continue to advocate for stronger action to replace animals in
medical research. working in partnership with others.
Progress
More Actlon Needed
E60m investment
Limited focus on basic research
Human-relevant models supported
No clear replacement roadmap
Improved validation pathways
Further advocacy required
ee
Whilst we welcome the Government's commitment to
alternative methods and human-relevant models, stronger
action is still needed to replace animals in medical
research.
27

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Thank yous
ee
The progress highlighted in these pages reflects the generosity,
dedication and belief of our supporters.
Their commitment enables vital work that would not otherwise be
possible. Thank you for standing with us and helping to drive
meaningful change for animals.
1130
2220
£64K
Donors
Supporters
Ralsed
Thanks to the unwavering support of our community. this has been a year of significant
progress for animals.
With the backing of 2,220 supporters and 1,130 donors, we raised £63,911. With this, we
have been able to invest in innovative. human-relevant research and accelerate our
mission to replace the use of animals in science.
The following pages celebrate the remarkable contribution of our supporters and the
impact we have achieved together.
28

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Public support and fundraising
The Trust's income is raised entirely from members of the public. through gifts in wills.
donations, fundraising activities, in memoriam donations, and shop sales. We are enormously
grateful for the generosity of everyone who has supported the Trust during the period. It is
only through their actions that we can continue our work.
Thank you to Alexei Gaynanov. who raised over £2,000
including Gift Aid for us running in the London
Marathon in April 2025.
Thank you to Arrandeep Heer-wilson, who organised a
charity dinner and dance which raised £600 for us.
Gifts in wills
We are hugely grateful to the following people who
so generously left us gifts in their wills..
Betty Eattersby, Harold Beeching, Amey Bromley.
Prudence Buck, Eileen Calder, Charlotte Clayton. Janet
Dale, M Date, S Donnelly. Edna Hames, Janet Harding.
Susan Holt, David Mayer. Maria Moore, Eric Palmer
Elisabeth and Victor Parker Derek Spraggs, Pauline
Sugden, Patricia Stride, Patricia Trow. Elaine Tubby.
Alexei Gaynanov. after
completing the London Marathon
Support through our gift shop
We have maintained our mail order catalogue and online gift shop, recognising
their importance as tools for promoting the Trust and reaching new audiences.
Support from shop customer5 continues to make a valuable contribution to the
Trust. As well as generating important income. the shop helps introduce new
people to THRT and our work.
29

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Volunteers and ambassadors
The Humane Research Trust is powered by a remarkable community of supporters who
give their time, energy and expertise to help advance animal-free medical rèsearch.
From fundraising and public engagement to raising awareness in their local
communities, our volunteers and ambassadors play an essential role In helping us reach
new audiences and inspire support for our mission.
Throughout the year, volunteers assisted with mailings. represented the Trust at
community events. and delivered talks to local groups, helping more people learn about
the Importance of replacing animals in research with human-relevant methods. Their
enthusiasm and commitment continue to strengthen our impact across the UK.
We are also grateful to Chris Packham and Megan Mccubbin, whose support has
helped raise awareness of the Trust and the growing movement towards animal-free
science. During the year, they supported our activities on social media and helped
judge our annual wildlife and companion animal calendar competition, bringing the
Trust's work to wider audiences.
30

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Acknowledgements
Our achievements are made possible by the dedication of a small and highly committed
team of staff. trustees and members of our Independent Scientific Advisory Panel,
Special thanks are given to the Trust's small staff team comprising the Chief Executive
Officer, the Trust Secretary, Administrator and Marketing & Communications Manager for
their exceptional efforts to ensure a continued high standard of service to grantholders,
donors, and supporters. In addition, the trustees thank Tim Askham, the consultant finance
officer. for his continued support with the Trust's financial management.
We would like to thank all the independent scientific advisory panel members who have
provided their invaluable expertise in the assessment of grant applications this year. Their
expertise ensures that every grant application is rigorously assessed and that the Trust
operates to the highest standards of governance and scientific excellence,
We were delighted to win the Best Not-for-profit Organisation award at the 2025
Stockport Business Awards in November. The award recognised our clear mission and
purpose, our performance against our aims. and our plans for the future. This recognition
reflects the collective impact of our supporters, partners, researchers, volunteers and staff,
all working together towards a future where medical discoveries no longer depend on
animal experiments.
The THR T Team at the
Stockport Business Awards
31

The Humane
Research Trust CIO
Helping people, savin9 artymals
ENVIRONMENTAL, SOCIAL AND
GOVERNANCE STRATEGY
Marketlng
Flnance
Operatlons

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
GOVERNANCE AND
FINANCIALS
Our governance framework
The Humane Research Trust CIO is an incorporated registered charity, number 1203103,
under a constitution signed by the founding trustees on 17 May 2023.
The Trust is governed by a board of trustees. All trustees give the1r time freely and no
remuneration is paid to any trustee. The trustees who served during the period are listed
on page 40.
The board of trustees holds four Board meetings a year to agree the overall strategy,
policies, and areas of activity. Trustees make decisions on new grants and keep financial
performance, reserves, risk and incident management under review. The board of trustees
has powers to delegate some decision-making to sub-committees of the 8oard. During the
period, sub-committees operated in the four areas of audit & finance. operations, science,
and marketing & fundraising. Each sub-committee has terms of reference that are kept
under review.
Trustees are required to disclose all relevant interests and register them with the chair of
the Board and in accordance with the Trust's policy withdraw from discussions where a
conflict of Interest exists. Details of trustees. expenses and related party transactions are
stated in the notes to the financial statements.
33

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Charitable objects
The charitable objects of the Trust are the promotior) and encouragement of medical and
scientific research and learning and the dissemination of the results of such research for
the benefit of the public and in particular (but without prejudice to the generality of the
foregoing) in fields that may lead to the elimination of the use of animals and animal
products I n medical and scientific research and in all kinds of testing.
The Trust, which relies entirely on public donations and fundraising activities. online shop
sales and legacies, ende3vours to raise finance for pioneering projects in the UK that lead
to improvements in medical research techniques, the advancement of diagnosis and
treatment of human diseases and the development of innovative alternatives to the use of
animals and animal-derived products in medical research.
Future plans
As this reporting period marked the final year of our 2023-26 strategy, the next financial
period will see the refresh of our strategy. We expect to continue to focus our resources
on funding high-quality research to accelerate the development and use of methods to
replace animals in medical research.
A key consideration will be how we can best support scientists to develop approaches that
can be adopted and validated by others This will help build wider trust in anim81-free
science.
34

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Appointment of trustees
The appointment of trustees is governed by the Trust's Constitution, and the board of
trustees is authorised to appoint new trustees to fill vacancies arisirng from retirement,
resignation or death of an existing trustee. Trustees serve for a 3-year term and can stand
for re-appointment for a second 3-year term. The trustees nominate a chair and deputy
chair from amongst their number.
To provide the strategic leadership that is necessary for the Trust, the board keeps the skill
requirements for the trust body under review. Potential new trustees are identified through
open competition, personal recommendation or through knowledge of individuals who
respect the ethos of the Trust. Candidates are interviewed by a panel of existing trustees
and appointments are made subject to candidates meeting trustee eligibility criteria and
the completion of a conflicts of interest declaration.
The Constitution provides for a minimum of three trustees and a maximum of eleven
trustees, During the period two trustees resigned and two new trustees were recruited
who will join the Board in June 2026.
The trustees all have a professional background, and two are actively involved in medical
research. Trustees may seek independent opinions. as appropriate. from members of the
Trust's independent Scientific Advisory Panel or from other specialist advisers from time to
time.
Training of trustees
The induction process for any newly appointed trustee comprises meetings with the chair
of trustees to explain the powers and responsibilities of the board and to provide a brief
history of the Trust
Trustees are given copies of key policy documents, the governing
constitution, copy minutes and annual reports and accounts together
with other financial information. Additionally. any new trustee is mado.
aware of the Charity Commission's guidance".
'The Essential Trustee.. What you need to know..
35

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Risk and incident management
The Trust maintains a register of the key risks facing the charity. The risks fall into three
categories.. f i nancial, operational. and reputational.
Each risk is owned by a Board sub-committee that reviews the risks and the
corresponding preventive and mitigating actions on a quarterly basis. The board of
trustees review5 the register on an annual basis.
Further. an incident log is maintained to keep trustees informed of issues that have arisen
across the Charity. how they have been dealt with and whether the relevant policies and
procedures were fit for purpose or need revision.
36

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Investment powers and objectives
The constitution authorises the trustees to make and hold investments, at their
discretion, using the general funds of the charity. During the accounting period of this
report the portion of the Trust's reserves not expected to be utilised within three years
was placed in the ethical Investment fund managed by CCLA. a specialist charity fund
manager.
The Board reviews the rjerformance of its investments at each meeting and, following an
extended period of poor performance of CCLA compared to other funds, investigated
alternative fund managers. The fund manager Quilter has been appointed
Other reserves remain on deposit with a panel of regulated banking institutions,
including with the principal banker, and in CCLA'S Deposit Fund.
Public benefit
The trustees, having had regard to guidance on public benefit issued by the Charity
Commission, confirm that the charitable purposes of the Trust fall within the definitions
set out in the Charities Act and, therefore. are for the public benefit.
37

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Grant making policy
The Trust invites grant applications from UK-based scientists from a diverse range of
disciplines. Details of how to apply for grants are published on the charity's website.
All applications are assessed and scored by three members of the Trust's independent
Scientific Advisory Panel for their scier)tific merit and against the research objectives
established by the trustees. A panel meeting is held with all the assessors to review and
moderate the scores. In some cases, applicants are Invited to interview or are visited
prior to a final decision by the Trust board's science sub-committee on which
applications to fund.
The Trust currently funds PhD studentships, early career post-doctoral research
scientists and fellowships Projects cover a wide range of animal-free techniques and
human diseases. A cornerstone of the Trust's philosophy is to encourage scientists to
develop innovative alternatives to the use of animals in medical research and to fulfil a
key role in nurturing the next generation of medical researchers.
The trustees reouire grantees to issue reports at not less than annual intervals to enable
them to monitor progress of the projects. On completion a final report Is required that
details the research undertaken, key findings, publications and presentations arising, and
the next steps for the research. The trustees use the number of academic papers
accepted for publication, Independent editorial endorsements and citations of these,
together with presentations at scientific conferences. as an indicator of impact.
Grant recipients may be asked to produce articles for inclusion in the charity's l iterature
and to make presentations at internal conferences and seminars. Communication with
grantees is a continual process.
38

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Our People
Staff
Day-to-day operations. grant administration and the management of grant applications
were delegated to the Trust's staff team. comprising the CEO. Trust Secretary,
Administrator, and Marketing & Communications Manager. The Trust also retained a
consultant Finance Officer. Together. they support the charity's governance and delivery
of its charitable objectives.
The salaries of the Trust's employees are reviewed annually by the Board with reference
to average earnings in the charity sector for charities of equivalent size, and to the cost
of living
Independent sclentlflc advlsory panel
Grant applications are peer reviewed by the Trust's independent Scientific Advisory
Panel, whose members also support other Trust activities as required The panel includes
current and former grant holders. together with scientists recruited through open calls
on the Trust's website and social media channels Panel members are not remunerated.
The Trust has a conflicts of interest policy in place to maintain the objectivity and
fairness of the grant application assessment process. Conflicts of interest among panel
members can i nclude direct or Indirect financial ties to the applicant or their Institution,
personal or academic relationships with the applicants, or other competing loyalties
Volunteers
The Trust calls upon a considerable number of volunteers throughout the UK to assist
with fundraising activities on behalf of the Charity and to promote its objectives and
activities. The Trust has a policy in place for the recruitment and management of its
volunteers.
In the absence of reliable information, which would impose additional
demands upon the volunteers. it is not practicable to give an indicative
value of unpaid voluntary assistance.
39

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Reference and administrative details
in
Janet Tate-smith
(chair)
Trustees:
lJu12023
Barry Topham
(deputy chairl
l Jul 2023
Paul Gold
lJul 2023
Bryan Homan
lJu12023
12 Mar 2026
Gillian Homan
lJul 2023
Prof Julie Gough
lJul 2023
Kelly Ryan
lJul 2023
Prof Aline M iller
8 Sept 2023
5 Dec 2025
Alan Crozier IHon
Treasurer)
8 Sept 2023
Natalie Bennett
114Jun 2024
Sam Worthington
114Jun 2024
Charlty Off Ice: Brook House. 29 Bramhall Lane South. Bramhall, SK7 2DN
Audltors: Harold Sharp Limited. 5 Brooklands Place, Brooklands Road, Sale. M33 3SD
Bankers: Royal Bank of Scotland. 36 St Andrew Square. Edinburgh. EH2 2YB
40

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Financial Position
The trustees of The Humane Research Trust CIO F)resent the financial statements of the
charity for the 12-month period from l April 2025 to 31 March 2026. The financial
statements have been prepared in accordance with the accounting policies set out on
page 56 and comply with the charity s constitution and "Accounting and Reporting by
Charities.. Statement of Recommended Practice applicable to charities preparing their
ccounts in accordance with the Financial Reporting Standard applicable in the UK and
Republic of Ireland effective l January 2015.
For the reporting period. the Board planned to run a £907.660 deficit. At year-end. the
Trust recorded a deficit of £1,052,692. The main contributing factor to the larger than
forecast deficit was unrealised losses in our invested portfolio.
The income of the Trust for the 12-month period ended 31 March 2026 totalled £651,187.
Legacy income was £361,408, significantly down on the previous period (£1,585,185), but
continues to be the dominant source of income for the Trust.
Donations were £63,911 including gift aid. The Trust is grateful to its dedicated supporters
for their continuing support.
In respect of investment returns in the period. £126,132 was earned from interest on
deposited reserves. The Trust's policy is to account for interest only as received. In
addition, investment income received from dividends & fixed income yields totalled
£77,996. On the other hand, our combined invested reserves experienced unrealised
valuation losses of £222,190. Accordingly. this amounted to a combined total negative
return of £18,062 over 12 months representing approximately -0.3% p.a. on our average
investible reserves. It should be noted that 31 March 2026 was an especially low point for
investment returns so far in 2026.
41

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Governance and support costs during the 12-month period amounted to £309,443. The
Trust's priority is to fund high quality research. and trustees therefore keep operating
expenses to a minimum, reflected in a small staff base and focused activities.
When setting the annual budget and taking decisions on grants. the Trust aims to keep
operating costs (excluding shop stock purchases) to within 33-50% of grant expenditure.
In the period the ratio was 26%.
A second metric is to endeavour to keep operating costs (excluding shop stock purchases)
within 25-33Qh of income (excluding shop sales). During the period the figure was 48°A
owing to a combination of lower income from legacies than in recent years and a
reduction in returns classed as income as funds were moved from deposit to equities
Re-imbursement of expenditure on grant awards made by the Trust amounted to
£1,159,797 during the period. This was significantly up on the previous period, reflecting the
Trust's increased investment in research over the last two years.
The Trust continues to be financially sound with total assets minus commitments standing
at £2.7m. This allow5 the Board to continue to pursue leading edge research projects that
fit with the Trust's ethos and represent good value for money.
42

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Investments
The charity held £2,361,234 in the Ethical Investment Fund managed by CCLA, comprising
both income and accumulation units. Other reserves (£3m) were substantially held on
deposit both with various UK regulated banking institutions. in Rathbones High Liquidity
Fund and CCLA'S deposit fund.
The CCLA Ethical Investment Fund has underperformed over the past few years,
prompting trustees to review alternative funds. Trustees were pleased to identify Quilter
Investor's Ethical Investment Fund as a suitable alternative that is high-performing end
excludes all animal testing and intensive farming practices.
The Trust is trarnsitionirng all its funds from the CCLA Ethical Investment Fund to Quilter
Investor's Ethical Investment Fund over the course of the next reporting period.
43

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Reserves policy
The trustees aim to maintain free reserves in unrestricted funds at a level to ensure that
operational and governance costs are covered for the period over which the Trust's grant
commitments extend.
As stated in note 17 on page 66 of the financial statements. the trustees have agreed to
make future grant payments amounting to £2.3m until December 2029. The Trust
therefore aims to maintain free reserves to cover the operational and governance costs
through to 2029. Operational and governance costs are calculated using current costs for
the first two years, tapering down over subsequent years.
Legacy Income is the dominant income stream of the Trust, with unpredictability in both
timing and amount. Grant commitments are normally for research projects of between two
and four years, Consequently, there can be time lags between receipt of income and
payment of grants. Therefore. the Trust can. and frequently does, hold reserves greater
than the amount needed to meet its operational and governance costs for the
duration of the grants awarded.
44

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Statement of the Trustees,
responsibilities
The trustees are responsible for preparing the trustees. annual report and the financial
statements in accordance with applicable law and United Kingdom Accounting Standards
(United Kingdom Generally Accepted Accounting Practice).
The law applicable to charities in England and Wales. and the provisions of the Trust's
constitution, requires the trustees to prepare financial statements for each financial year
which give a true and fair view of the state of affairs of the Trust and of the incoming
resources and application of resources, including the income and expenditure, of the Trust
for that period. In preparing these financial statements, the trustees are required to..
select suitable accounting policies and then apply them consistently..
observe the methods and principles in the charities SORP..
make judgements and estimates that are reasonable and prudent.,
state whether applicable accounting standards have been followed, subject to any
material departures disclosed and explained in the financial statements., and
prepare the financial statements on the going concern basis unless it is Inappropriate
to presume that the charity will continue in business.
The trustees are responsible for keeping proper accounting records that disclose with
reasonable accuracy at any time the financial position of the Trust and enable them to
ensure that the financial statements comply with the charity's governing document, the
Charities Act 2011 and the relevant version of the Statement of Recommended Practice
appl icable to charities preparing their accounts in accordance with the Financial Reporting
Standard applicable in the UK and Republic of Ireland (FRS 102). They are also responsible
for safeguarding the assets of the Trust and hence for taking reasonable steps for the
prevention and detection of fraud and other irregularities.
Approval
This report was approved by the trustees on the 11/09/26 and signed
on their behalf.
Janet Tate-smith
Chair of trustees
45
15.10.2026

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Independent Auditor's Report
to the Members and Trustees of
The Humane Research Trust CIO
We have audited the financial statements of The Humane Research Trust CIO (the
'charity') for the year ended 31 March 2026 which comprise the Statement of Financial
Activities, the Balance Sheet. the Cash Flow Statement and the related notes.
The financial reporting framework that has been applied in their preparation is applicable
law and United Kingdom Accounting Standards, including Financial F2eporting Standard
102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United
Kingdom Generally Accepted Accounting Practice).
In our opinion, the f inancial statements..
give a true and fair view of the state of the charity's affairs as at 31 March 2026, and of
its incoming resources and application of resources. for the year then ended,
have been properly prepared in accordance with United Kingdom Generally Accepted
Accounting Practice., and
have been prepared in accordance with the requirements of Charities Act 2011.
Basls for oplnlon
We conducted our audit in accordance with International Standards on auditing (UK)
(ISAS (UK)) and applicable law. Our responsibilities under those standards are further
described in the Auditor's responsibilities for the audit of the financial statements
section of our report. We are independent of the charity in accordance with the ethical
requ Irements that are relevant to our audit of the financial statements In the
UK, Including the FRC'S Ethical Standard, and we have fulfilled our other
ethical responsi bi l ities in accordance with these requirements.
We believe that the audit evidence we have obtained is
sufficient and appropriate to provide a basis for our
opinion.
46

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Basls for oplnlon
We conducted our audit in accordance with International Standards on auditing (UK)
(ISAS (UK)) and applicable law. Our responsibilities under those standards are furthèr
descri bed in the Auditor's responsibilities for the audit of the financial statements section
of our report. We are independent of the charity in accordance with the ethical
requ irements that are relevant to our audit of the f inancial statements in the LJK, includi ng
the FRC'S Ethical Standard. and we have fulfilled our other ethical responsibilities in
accordance with these requirements. We believe that the audit evidence we have obtained
is sufficient and appropriate to provide a basis for our opinion.
Conclusions relation to going concern
In auditing the financial statements. we have concluded that the trustees, use of the
going concern basis of accounting in the preparation of the financial statements is
appropriate.
Based on the work we have performed, we have not identified any material uncertainties
relating to events or conditions that. individually or collectively. may cast signif icant doubt
on the charity's ability to continue as a going concern for a period of at least twelve
months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern
are described In the relevant sections of this report.
47

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Other information
The other information comprises the information included in the annual report. other than
the financial statements and our auditor's report thereon. The trustees are responsible for
the other information, Our opinion on the financial statements does not cover the other
information and we do not express any form of assurance conclusion thereon. In
connection with our audit of the financial statements, our responsibility is to read the
other information and, in doing so, consider whether the other information is materially
inconsistent with the financial statements or our knowledge obtained in the audit or
otherwise appears to be materially misstated.
If we identify such material inconsistencies or apparent material misstatements. we are
required to determine whether there is a material misstatement In the financial statements
or a material misstatement of the other information. If. based on the work we have
performed, we conclude that there is a material misstatement of this other information, we
are required to report that fact.
We have nothing to report in this regard.
Matters on whlch we are required to report by exception
We have nothing to report in respect of the following matters where the Charities
(Accounts and Reports) Regulations 2008 requires us to report to you if, In our opinion..
the i nformation given in the financial statements is
inconsistent in any material respect with the trustees.
report.,
sufficient accounting records have not been kept..
the financial statements are not in agreement with the
accounting records and returns. or
we have not received all the information and explanations
we require for our audit.
48

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
Responsibilities of trustees
As explained more fully in the Trustees, Responsibilities Statement set out on pa
e45the
trustees are responsible for the preparation of financial statements which give a true and
fair view, and for such Internal control as the trustees determine is necessary to enable the
preparation of firnancial statements that are free from material misstatement, whether due
to fraud or error.
In preparing the fir)ancial statements. the trustees are responsible for assessing the
charity's abil Ity to continue as a going concern, disclosing, as applicable. matters related to
going concern and using the going concern basis of accounting unless the trustees either
intend to liquidate the company or to cease operations. or have no realistic alternative but
to do so.
Audltor's responslbilitles for the audlt of the financial statements
We have been appointed as auditor under the Charities Act 2011, s. 144 and report In
accordance with regulations made under the Act and relevant regulations made or having
effect thereunder.
Our objectives are to obtain reasonable assurance about whether the financial statements
as a whole are free from material misstatement, whether due to fraud or error, and to issue
an auditor's report that includes our opinion. Reasonable assurance is a high level of
assurance, but is not a guarantee that an audit conducted in accordance with ISAS (UK)
will always detect a material misstatement when it exists. Misstatemernts can arise from
fraud or error and are considered material if. individually or in the aggregate, they could
reasonably be expected to Influence the economic decisions of users taken on the basis of
these f i nancial statements.
49

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
The extent to which our procedures are capable of detecting irregularities, including fraud
is detailed below:
We obtained an understanding of laws, regulations and guidance that affect the
Charity, focusing on those that had a direct effect on the financial statements or that
had a fundamental effect on its operations. Key laws, regulations and guidance that we
identif led included the Charities Act 2011 and relevant tax legislation.
We enquired of the Trustees and reviewed correspondence and Trustee meeting
minutes for evidence of non-compliance with relevant laws and regulations,
We gair)ed an understanding of the controls that the Trustees have in place to prevent
and detect fraud. We enquired of the Trustees about any incidences of fraud that had
taken place during the accounting period.
The risk of fraud and non-compliance with laws and regulations was discussed within
the audit team and tests were planned and performed to address these risks
We reviewed financial statements disclosures and supporting documentation to assess
compliance with relevant laws and regulations discussed above.
We enquired of the Trustees about actual and potential litigation and claims.
We performed analytical procedures to identify any unusual or unexpected
relationships that might indicate risk of material misstatement due to fraud.
In addressing the risk of fraud due to management override of internal controls we
tested the appropriateness of journal entries and assessed whether the judgements
made in making accounting estimates were indicative of a potential bias.
50

The Humane
Research Trust CIO
Helpiny people, saviil9 artymals
There are inherent limitations in our audit procedures described above. The more
removed that laws and regulations are from financial transactions. the less likely it is that
we would become aware of non-compliance. Auditing standards also limit the aLJdit
procedures required to identify non-compliance with laws and regulations to enquiry of
the directors and other management and the inspection of regulatory and legal
correspondence, if any.
Material misstatements that arise due to fraud can be harder to detect than those that
arise from error as they may involve deliberate concealment or collusion.
A f urther description of our responsibilities for the audit of the f inancial statements is
located on the Financial Qeporting Council's website at..
www.frc org uk/auditorsresponsibilities.
This description forms part of our auditor's report.
Use of our report
This report is made solely to the charity's trustees, as a body. in accordance with Part 4 of
the Charities (Accounts and Reports) Regulations 2008. Our audit work has been
undertaken so that we might state to the charity's trustees those matters we are required
to state to them in an auditor's report and for no other purpose.
To the fullest extent permitted by law. we do not accept or assume responsibility to
anyone other than the charity and the charity's trustees as a body, for our audit work, for
this report, or for the opinions we have formed.
Frederick Norman
Senior Statutory Auditor
for and on behalf of Harold Sharp Limited
Chartered Accountants and Statutory Auditor
5 8rooklands Place, Sale M33 SSD
Date: 15.10.2026
51

**THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE PERIOD 1 APRIL 2025 TO 31 MARCH 2026** 

|Notes<br>**Income & Endowments From**<br>Donations & legacies<br>2<br>Other trading activities<br>3<br>Investment Income<br>4<br>**Total**<br>**Income**<br>**Expenditure On**<br>Raising<br>Funds<br>5<br>**Charitable activities**<br>Grants<br>6<br>Governance<br>6<br>Other<br>6<br>**Total Expenditure**<br>Net Gains/(Losses) on investments<br>**Net Income/(Expenditure)**<br>**Reconciliation of Funds**<br>Total Funds brought forward<br>**Total Funds carried forward**|**Unrestricted**<br>**Fund**<br>**Restricted**<br>**Fund**<br>**Total**<br>**Funds**<br>Total<br>Funds<br>**01.04.25 to**<br>**31.03.26**<br>01.04.24to<br>31.03.25<br>(Restated)<br>**£**<br>**£**<br>**£**<br>£<br>**425,319**<br>**-**<br>**425,319**<br>1,660,035<br>**21,740**<br>**-**<br>**21,740**<br>21,478<br>**204,128**<br>**-**<br>**204,128**<br>216,638|
|---|---|
||**651,187**<br>**-**<br>**651,187**<br>1,898,151<br>**(136,594)**<br>**-**<br>**(136,594)**<br>(124,437)<br>**(1,236,728)**<br>**-**<br>**(1,236,728)**<br>(781,306)<br>**(11,977)**<br>**-**<br>**(11,977)**<br>(15,559)<br>**(96,3**<br>**0)**<br>**-**<br>**(96,390)**<br>(97,240)|
||**(1,481,689)**<br>**-**<br>**(1,481,689)**|
||**(222,190)**<br>**-**<br>**(222,190)**<br>(87,527)|
||**(1,052,692)**<br>**-**<br>**(1,052,692)**<br>792,082<br>**6,086,449**<br>**-**<br>**6,086,449**<br>5,294,367|
||**5,033,757**<br>**-**<br>**5,033,757**<br>6,086,449|



The notes on page 55 to 67 form part of these financial statements. 

52 



**THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **BALANCE SHEET 31 MARCH 2026** 

|Notes<br>**Fixed Assets**<br>Tangible Assets<br>11<br>Investments<br>12<br>**Current Assets**<br>Stock<br>13<br>Debtors<br>14<br>Cash at bank and in hand<br>Current Asset investments<br>12<br>**Creditors**<br>Amounts falling due within one year<br>15<br>**Net Current Assets**<br>**Total Assets less Current Liabilities**<br>**Net Assets**<br>**Funds**<br>Unrestricted Funds<br>Restricted Funds<br>**Total**<br>**Funds**|**Unrestricted**<br>**Fund**<br>**Restricted**<br>**Fund**<br>**£**<br>**£**<br>**51,122**<br>**-**<br>**3,087,465**|<br> <br>**2026**<br>2025<br>**Total**<br>**Funds**<br>Total<br>Funds<br>**£**<br>£<br>**51,122**<br>53,042<br>**3,087,465**<br>2,277,464|
|---|---|---|
||**3,138,587**<br>**-**<br>**5,455**<br>**-**<br>**65,410**<br>**-**<br>**1,796,783**<br>**-**<br>**467,044**|**3,138,587**<br>2,330,506<br>**5,455**<br>7,165<br>**65,410**<br>33,629<br>**1,796,783**<br>3,010,267<br>**467,044**<br>1,033,223|
||**2,334,692**<br>**-**<br>**(439,522)**<br>**-**|**2,334,692**<br>4,084,284<br>**(439,522)**<br>(328,341)|
||**1,895,170**<br>**-**|**1,895,170**<br>3,775,943|
||**5,033,757**<br>**-**|**5,033,757**<br>6,086,449<br>**5,033,757**<br>6,086,449|
||**5,033,757**<br>**-**||
|||**5,033,757**<br>6,08<br>,449<br>**-**<br>**5,033,757**<br>6,08<br>,449|



The financial statements were approved by the Board of Trustees on 11 September 2026 and were signed on its behalf by: 


**……………………. Janet Tate-Smith Chair of trustees** 

**……………………. Alan Crozier Honorary Treasurer** 

**Oct 15, 2026** 

53 



## **THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **CASH FLOW STATEMENT FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

|Notes<br>**Cash flows from operating activities**<br>Cash generated from operations<br>1<br>Net cash provided by operating activities<br>**Cash flows from investing activities**<br>Purchase of tangible fixed assets<br>Purchase of fixed asset investments<br>Interest received<br>Net cash provided by/(used in) investing activities<br>**Change in cash and cash equivalents in the**<br>**reporting period**<br>**Allocation to current asset investments**<br>**Cash and cash equivalents at the beginning of the**<br>**reporting period**<br>**Cash and cash equivalents at the end of the**<br>**reporting period**|**Period**<br>Period<br>**01.04.25 to**<br>**31.03.26**<br>01.04.24 to<br>31.03.25<br>**£**<br>£<br>**(870,937)**<br>841,411|
|---|---|
||**(870,937)**<br>841,411|
||**(2,666)**<br>(6,475)<br>**(1,034,977)**<br>(200,000)<br>**126,132**<br>176,228|
||**(911,511)**<br>(30,247)|
||**(1,782,448)**<br>811,164<br>**568,964**<br>(1,033,223)<br>**3,010,267**<br>3,232,326<br>**1,796,783**<br>3,010,267|



54 



## **THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE CASHFLOW STATEMENT FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **1. RECONCILIATION OF NET INCOME/EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES** 

|**Net income/(expenditure) for the reporting period**<br>Adjustments for:<br>Depreciation Charges<br>Losses/(gains) on Fixed Asset Disposals<br>Losses/(gain) on investments<br>Interest received<br>(Increase) in stocks<br>Decrease/(increase) in debtors<br>Increase in creditors<br>**Net cash provided by operations**|**Period**<br>Period<br>**01.04.25 to**<br>**31.03.26**<br>01.04.24 to<br>31.03.25<br>**£**<br>£<br>**(1,052,692)**<br>792,082<br>**4,586**<br>4,931<br>**-**<br>1,715<br>**222,191**<br>87,527<br>**(126,132)**<br>(176,228)<br>**1,710**<br>(2,050)<br>**(31,781)**<br>48,509<br>**111,181**<br>84,925<br>**(870,937)**<br>841,411|
|---|---|



**2. ANALYSIS OF CHANGES IN NET FUNDS** 

|**Net Cash**<br>Cash at bank and in hand<br>**Total**|At<br>01.04.2025<br>Cash flow<br>Reallocation<br>At<br>31.03.2026<br>£<br>£<br>£<br>£<br>3,010,267<br>(1,782,448)<br>568,964<br>1,796,783<br>**3,010,267**<br>**(1,782,448)**<br>**568,964**<br>**1,796,783**|
|---|---|



55 



## **THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

**NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **1. ACCOUNTING POLICIES** 

## **1.1 Basis of preparation of the financial statements** 

The accounts (financial statements) have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice. 

The accounts (financial statements) have been prepared to give a ‘true and fair’ view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a ‘true and fair view’. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn. 

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s) and with the exception of investments which are included at market value. 

The Charity incorporated as a charitable incorporated organisation on the 1[st] July 2023, with the transfer of activities from the previous unincorporated charity The Humane Research Trust. In line with the requirements of the Charities SORP this formation has been treated as a merger. As a result the asset and liabilities of the previous entity were transferred at book value to the Charity with no adjustments considered necessary. All results in the current period relate solely to the new Charity. 

## **1.2 Going concern** 

The accounts have been drawn up on a going concern basis.  In common with many fund-raising charities, the adoption of the going concern basis is dependent on the company receiving adequate fundraising from voluntary income such as donations and legacies. While the Trustees recognise the uncertainties inherent in predicting the timing and level of future funding from voluntary income that is not yet assured, they believe that adequate funding will be secured from donations and legacies. 

## **1.3 Income** 

_Legacies_ 

Legacies are recognised in the period in which the charity becomes legally entitled to the income, notification has been received and the amount can be quantified with reasonable accuracy. It is categorised as unrestricted or restricted funds dependent upon whether expenditure restrictions by donors are placed on such receipts.  Donated investments are introduced at the market value at the date of receipt. 

## _Direct giving, fundraising and gift aid_ 

Cash donations are recognised as they are received along with relevant gift aids amounts if applicable. 

## **1.4    Expenditure** 

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category.  Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

56 



## **THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **1. ACCOUNTING POLICIES - continued** 

## _Raising donations and legacies_ 

These include salaries and directly attributable overheads, plus a proportion of central support costs. _Grants_ 

These include amounts paid to grant recipients. _Governance related_ 

These are the central running costs of the Charity, including strategic oversight and public accountability. 

## _Other support costs_ 

These are other ancillary costs, such as IT costs, not directly related to the activities of the Charity. 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Grants offered subject to conditions which have not been met are noted as a commitment but not accrued as expenditure. 

## **1.5     Tangible fixed assets** 

Assets costing more than £500 are capitalised and accounted for at historical cost. Depreciation is provided on all tangible fixed assets for Charity use over their useful economic lives at the following rates: 

Freehold property 2% per annum on reducing value Fixtures, fittings and office equipment 20% per annum on reducing value 

Freehold property 

## **1.6 Stock** 

Stocks are valued at the lower of cost and net realisable value. 

## **1.7 Taxation** 

The charity is exempt from corporation tax on its charitable activities under Section 505 of the Income and Corporation Taxes Act 1988 to the extent that they are applied to the organisation's charitable objects. 

## **1.8 Fund Accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. 

Restricted funds can only be used for particular restricted purposes within the objectives of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. 

## **1.9 Pension and other post-retirement benefits** 

The Charity operates a defined contribution pension scheme. Contributions payable to the pension scheme are charged to the Statement of Financial Activities in the period to which they relate. 

## **1.10 Investments** 

All investments are carried at fair value. Holdings in common investment funds restated at their midmarket price. The statement of financial activities includes the nets gains and losses arising on revaluations and disposals throughout the year. Asset sales and purchases are recognised at the date of trade at cost. Investments are managed using the total investment return methodology. 

Interest on deposited monies is recognised only on receipt. 

57 



## **THE HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **2. DONATIONS AND LEGACIES** 

|Donations<br>Gift Aid<br>Legacies<br>**3.**<br>**OTHER TRADING ACTIVITIES**<br>Shop income<br>**4.**<br>**INVESTMENT INCOME**<br>Deposit account interest<br>Investment income<br>**5.**<br>**RAISING FUNDS**<br>**Raising donations and legacies**<br>Marketing materials<br>and distribution<br>IT Costs<br>Support Costs||**Period**<br>**01.04.25 to**<br>**31.03.26**<br>**£**<br>**55,510**<br>**8,401**<br>**361,408**<br>**425,319**<br>**Period**<br>**01.04.25 to**<br>**31.03.26**<br>**£**<br>**21,740**<br>**Period**<br>**01.04.25 to**<br>**31.03.26**<br>**£**<br>**126,132**<br>**77,996**<br>**204,128**<br>**Period**<br>**01.04.25 to**<br>**31.03.26**<br>**£**<br>**23,850**<br>**2,880**<br>**98,916**<br>**125,646**|Period<br>01.04.24 to<br>31.03.25<br>£<br>69,856<br>4,994<br>1,585,185<br>1,660,035<br>Period<br>01.04.24 to<br>31.03.25<br>**£**<br>21,478<br>Period<br>01.04.24 to<br>31.03.25<br>**£**<br>176,228<br>40,410<br>216,638<br>Period<br>01.04.24 to<br>31.03.25<br>(Restated)<br>**£**<br>,9<br>1,993<br>,<br>108,435|
|---|---|---|---|



58 



## **HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

**FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **5. RAISING FUNDS - continued** 

## **Other trading activities** 

|**ther trading activities**||||
|---|---|---|---|
|Purchases<br>Aggregate Amounts||**Period**<br>**01.04.25 to**<br>**31.03.26**<br>**£**<br>**10,948**|Period<br>01.04.24 to<br>31.03.25<br>**£**<br>16,002<br>124,437|
|||**136,594**||



## **Prior Year Restatement** 

In 2026 a revised analysis of salaries and other support costs between Grants, Governance, Fund raising activities better aligns with the SORP.  2025's allocation of these costs is restated on same basis. This has no impact on the Net Income or Total Reserves. 

## **6. CHARITABLE ACTIVITIES** 

## **Period to 31 March 2026** 

|Grants<br>Governance related<br>Other Support<br>costs|**Direct costs**<br>**Grant**<br>**funding**<br>**(note 7)**<br>**Support**<br>**costs**<br>**(note 8)**<br>**Totals**<br>**£**<br>1,501<br>1,159,797<br>75,430<br>1,236,728<br>1,323<br>-<br>10,654<br>11,977<br>-<br>-<br>96,390<br>96,390<br>2,824<br>1,159,797<br>182,474<br>1,345,095|
|---|---|



## **Period to 31 March 2025 (Restated)** 

|Grants<br>Governance related<br>Other Support<br>costs|**Direct costs**<br>**Grant**<br>**funding**<br>**Support**<br>**costs**<br>**(note 8)**<br>**Totals**<br>**£**<br>3,<br>712,254<br>5,<br>781,306<br>-<br>-<br>15,559<br>15,559<br>-<br>-<br>97,240<br>97,240<br>3,<br>712,254<br>1<br>8,<br>7<br>894,105|
|---|---|



59 



## **HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

**FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **7. GRANTS PAYABLE** 

The below outlines the grants which have been paid during the year 


**----- Start of picture text -----**<br>
Name and recipient  Purpose of grant  Amount (£)<br>institution<br> W , University of   4,851<br>East Anglia<br>Dr Rana, University of East  Defining a xeno-free human iPSC-derived 3D biomimetic vessel platform for   4,952<br>Anglia  the elucidation of mechanisms that drive vascular remodelling in pulmonary<br>arterial hypertension<br>Dr Schuller, University of  Development of a microaerobic human intestinal organoid model to determine<br>East Anglia  the role of the gut microbiome in Crohn’s disease   37,718<br>Dr Allan, de Montfort  Development of a humane respiratory epithelial model for pneumococcal  14,067<br>University  infection<br>Prof Gough, University of  Peptide based 3D in vitro platform for drug & toxicity testing   79,174<br>Manchester<br>Prof Madden, Liverpool John  In Silico Methods to Assist Development of Physiologically-Based Kinetic  44,989<br>Moores University   Models<br>Dr Bertuzzi, University of  Development of a next-generation animal-free microfluidic technology to  11,985<br>Manchester  understand antimicrobial immunity against lethal respiratory pathogens in the<br>lungs<br>Dr MacDonald, University of  Creating a Systems-level Model of the Neural Mechanisms Underlying   2,595<br>Birmingham  Impaired Impulse Control in Parkinson’s Disease<br>Dr Hodges, University of  Replacing animal testing with innovative spheroid models: targeted  16,070<br>Birmingham  nanoparticle therapy for head and neck cancer<br>Dr Boussahel, University of  A high throughput human vascularised 3D in-vitro model of adipose tissue to<br>Bristol  replace animal testing in drug development for metabolic dysfunction  28,963<br>Prof (Assoc) Nateri,  Development of 3D colorectal cancer patient-derived mini-ring model for high   62,528<br>University of Nottingham  throughput drug screening targeting the tumour microenvironment<br>Dr Rocha dos Santos,  A high-throughput human muscle model for sarcopenia research  37,413<br>Nottingham Trent University<br>Dr  Obaidi,  Advancing respiratory research with patient-specific data-driven lung models  52,176<br>University of Reading<br>Dr Orriss, Royal Veterinary  Developing non-animal ex vivo and in vitro models for studying arterial medial   55,808<br>College   calcification<br>Dr Green, University of  Hijack of the host: Uncovering how bacteria remodel human cell surface  14,124<br>Sheffield  proteins to promote infection<br>Dr Kang, University of  Cellular and molecular basis of neurodevelopmental disorders  31,897<br>Aberdeen<br>Dr George, Keele University  Manipulating ependymona oncogenic response using light-inducible genome   69,173<br>engineering and stem cells<br>Dr Selvaraj, University of  Mechanisms of neuro-muscular junction degeneration in Motor Neuron   179,944<br>Edinburgh  Disease (MND) using human(e) experimental models<br>Dr Theil, University of  Primary cilia and the control of neuronal network activity in  56,107<br>Edinburgh  neurodevelopmental disorders.<br>Prof Hosie, University of  Establishing a human tonsil organoid system to evaluate immune responses to  45,169<br>Glasgow  vaccination<br>Prof (Assoc) Campagnolo,  A 3D model of heart failure-associated microvascular dysfunction  66,303<br>University of Surrey<br>Prof Kalaskar, University  Developing and investigating the effectiveness of a fully artificial, animal-free  56,968<br>College London  vascular model to study the molecular factors governing blood vessel integrity<br>and function in health and disease<br>Dr Holloway, University of  Patient-derived brain vascular networks as a new in vitro model of cerebral  70,945<br>Oxford  small vessel disease: Studying the role of matrix remodelling in COL4A1 and<br>CARASIL<br>Prof Velliou, University  Developing fully synthetic, animal-free peptide based pancreatic cancer  72,218<br>College London  models: Unravelling the role of cell-matrix-peptide interplay on the disease<br>progression and drug response<br>Dr Bestmann, University  Understanding the dynamics of cortico-spinal interactions in humans  43,660<br>College London<br>Total 1,159,797<br>**----- End of picture text -----**<br>


60 



## **HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

**FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **7. GRANTS PAYABLE - continued** 

In assessing and considering grant applications, the Trustees encourage and support new medical research which does not include the use of animals, with the objective of advancing the diagnosis and treatment of disease in humans. The charity also encourages scientists to develop innovative alternatives to the use of animals in medical research and testing and fulfils an important role in educating the next generation of researchers. 

## **8. SUPPORT COSTS** 

|**Period to 31**<br>**March 2026**<br>Raising<br>Donations<br>Governance<br>Grants<br>Other<br>**Period to 31**<br>**March 2025**<br>**(Restated)**<br>Raising<br>Donations<br>Governance<br>Grants<br>Other|**Staff**<br>**Consulting**<br>**& prof fees**<br>**Advertising**<br>**&**<br>**Marketing**<br>**IT Costs**<br>**Other**<br>**support**<br>**costs**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>94,774<br>-<br>23,850<br>2,880<br>4,142<br>125,646<br>-<br>10,547<br>-<br>-<br>1,430<br>11,977<br>60,218<br>5,100<br>2,335<br>6,000<br>1,867<br>75,430<br>51,692<br>-<br>-<br>8,138<br>36,560<br>96,390|**Staff**<br>**Consulting**<br>**& prof fees**<br>**Advertising**<br>**&**<br>**Marketing**<br>**IT Costs**<br>**Other**<br>**support**<br>**costs**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>94,774<br>-<br>23,850<br>2,880<br>4,142<br>125,646<br>-<br>10,547<br>-<br>-<br>1,430<br>11,977<br>60,218<br>5,100<br>2,335<br>6,000<br>1,867<br>75,430<br>51,692<br>-<br>-<br>8,138<br>36,560<br>96,390|**Staff**<br>**Consulting**<br>**& prof fees**<br>**Advertising**<br>**&**<br>**Marketing**<br>**IT Costs**<br>**Other**<br>**support**<br>**costs**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>94,774<br>-<br>23,850<br>2,880<br>4,142<br>125,646<br>-<br>10,547<br>-<br>-<br>1,430<br>11,977<br>60,218<br>5,100<br>2,335<br>6,000<br>1,867<br>75,430<br>51,692<br>-<br>-<br>8,138<br>36,560<br>96,390|**Staff**<br>**Consulting**<br>**& prof fees**<br>**Advertising**<br>**&**<br>**Marketing**<br>**IT Costs**<br>**Other**<br>**support**<br>**costs**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>94,774<br>-<br>23,850<br>2,880<br>4,142<br>125,646<br>-<br>10,547<br>-<br>-<br>1,430<br>11,977<br>60,218<br>5,100<br>2,335<br>6,000<br>1,867<br>75,430<br>51,692<br>-<br>-<br>8,138<br>36,560<br>96,390|**Staff**<br>**Consulting**<br>**& prof fees**<br>**Advertising**<br>**&**<br>**Marketing**<br>**IT Costs**<br>**Other**<br>**support**<br>**costs**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>94,774<br>-<br>23,850<br>2,880<br>4,142<br>125,646<br>-<br>10,547<br>-<br>-<br>1,430<br>11,977<br>60,218<br>5,100<br>2,335<br>6,000<br>1,867<br>75,430<br>51,692<br>-<br>-<br>8,138<br>36,560<br>96,390|**Staff**<br>**Consulting**<br>**& prof fees**<br>**Advertising**<br>**&**<br>**Marketing**<br>**IT Costs**<br>**Other**<br>**support**<br>**costs**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>94,774<br>-<br>23,850<br>2,880<br>4,142<br>125,646<br>-<br>10,547<br>-<br>-<br>1,430<br>11,977<br>60,218<br>5,100<br>2,335<br>6,000<br>1,867<br>75,430<br>51,692<br>-<br>-<br>8,138<br>36,560<br>96,390|
|---|---|---|---|---|---|---|
||206,594<br>15,647<br>26,185<br>17,018<br>43,999<br>309,443||||||
||**Staff**<br>**Consulting**<br>**& prof fees**<br>**Advertising**<br>**&**<br>**Marketing**<br>**IT Costs**<br>**Other**<br>**support**<br>**costs**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>8<br>,<br>9<br>1<br>,<br>1,993<br>1<br>,43<br>-<br>2,08<br>15,559<br>5,<br>7,932<br>-<br>5,<br>7<br><br>2,164<br><br>-<br>-<br>-<br>-||||||
||,<br>1,474<br>1<br>,<br>4||||,|97,240|
||19|,<br>2<br>,||,<br>16,43<br>2<br>,|||



## **9. TRUSTEE REMUNERATION AND BENEFITS** 

No remuneration was paid to any trustee in the year (2025: None). 

## **10. STAFF COSTS** 

|Wages and Salaries<br>Social Security Costs<br>Other Pension Costs|**Period**<br>**01.04.25 to**<br>**31.03.26**<br>**£**<br>**164,815**<br>**10,890**<br>**30,889**<br>**206,594**|Period<br>01.04.24 to<br>31.03.25<br>**£**<br>149,653<br>10,736<br>30,907<br>191,296|
|---|---|---|



61 



## **HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

**FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **10. STAFF COSTS - continued** 

The average monthly number of employees during the period was as follows: 

||**Period**|Period|
|---|---|---|
||**01.04.25 to**|01.04.24 to|
||**31.03.26**|31.03.25|
||**£**|**£**|
|Administration|**4**|4|



One employee received emoluments in the band of £60,001 - £70,000 (2025: 1). 

## **11. TANGIBLE FIXED ASSETS** 

|**COST**<br>At 1 April 2025<br>Additions<br>Disposals<br>At 31 March 2026<br>**DEPRECIATION**<br>At 1 April 2025<br>Charge for period<br>Disposals<br>At 31 March 2026<br>**NET BOOK VALUE**<br>At 31 March 2026<br>At 1 April 2025|Freehold<br>property<br>£<br>67,546<br>-<br>67,546<br>31,513<br>746<br>-<br>32,259<br>35,287<br>36,033|Office<br>equipment<br>£<br>34,129<br>2,666<br>-<br>36,795<br>1<br>,<br>3,840<br>-<br>20,960<br>15,835<br>17,009|Total<br>£<br>101,675<br>2,666<br>-<br>104,341<br>48,633<br>4,586<br>-<br>53,219<br>51,122<br>53,042|
|---|---|---|---|



Freehold land and buildings were stated at their original historic cost in the accounts of The Lawson Tait Medical and Scientific Research Trust in May 1988, the date when the property was donated to The Humane Research Trust. 

The Trustees are of the opinion that the current market value of the freehold land and building is substantially in excess of its net book value. As the property is used solely for the administration of the Trust and there is currently no intention to see, the Trustees cannot justify the cost of a professional valuation. 

62 



## **HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

**FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **12. INVESTMENTS** 

|**MARKET VALUE**<br>At 1 April 2025<br>New Investments<br>Revaluations<br>At 31 March 2026<br>**NET BOOK VALUE**<br>At 31 March 2026<br>At 31 March 2025|Investments<br>£<br>**2,277,464**<br>**1,034,977**<br>**(224,976)**<br>**3,087,465**<br>**3,087,465**<br>2,277,464|
|---|---|



There were no investment assets outside the UK. These investments were held in the below: 

|CCLA ethical investment fund<br>Rathbone High Liquidity Fund<br>Bank Deposits (>3mths)<br>_Comparative figures_<br>CCLA ethical investment fund<br>Rathbone High Liquidity Fund<br>Bank Deposits (>3mths)|**Valuation at 31.03.26**<br>**£**<br>**2,361,234**<br>**687,231**<br>**39,000**<br>**3,087,465**<br>**Valuation at 31.03.25**<br>**£**<br>**2,277,464**<br>**-**<br>**-**<br>**2,277,464**|**Historical Cost at 31.03.26**<br>**£**<br>**2,450,000**<br>**695,977**<br>**39,000**<br>**3,184,977**<br>**Historical Cost at 31.03.25**<br>**£**<br>**2,150,000**<br>**-**<br>**-**<br>**2,150,000**|
|---|---|---|



63 



## **HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **12. INVESTMENTS (cont.)** 

Current asset investments represent balances held with a maturity of 3 months or less. At the year end the current assets investments were made up of: 

|**Valuation at 31.03.26**<br>**£**<br>Rathbone High Liquidity Fund<br>**302,444**<br>Bank Deposits (<3mths)<br>**164,600**<br>**467,044**<br>_Comparative figures_<br>**Valuation at 31.03.25**<br>**£**<br>Rathbone High Liquidity Fund<br>**-**<br>Bank Deposits (<3mths)<br>**1,033,223**<br>**1,033,223**<br>**Stock**<br>**2026**<br>Shop Stock<br>**5,455**<br>**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>**2026**<br>**£**<br>Prepayments<br>**12,080**<br>Accrued income<br>**53,330**<br>**65,410**|**Historical Cost at 31.03.26**<br>**£**<br>**300,562**<br>**164,600**<br>**465,162**<br>**Historical Cost at 31.03.25**<br>**£**<br>**-**<br>**1,033,223**<br>**1,033,223**<br>2025<br>7,165<br>2025<br>**£**<br>4,747<br>28,882<br>33,629|
|---|---|



## **13. Stock** 

## **14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR** 

64 



**HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR** 

|Trade Creditors<br>Social security and other taxes<br>Grants payable<br>Pensions payable<br>Accruals and deferred income|**2026**<br>**£**<br>**11,291**<br>**4,569**<br>**412,112**<br>**2,550**<br>**9,000**<br>**439,522**|2025<br>**£**<br>6,393<br>3,887<br>305,765<br>2,483<br>9,813<br>328,341|
|---|---|---|



## **16. MOVEMENT IN FUNDS** 

|**Unrestricted**<br>**Funds**<br>General Fund<br>**TOTAL FUNDS**|**At 01.04.2025**<br>**Net**<br>**Movement in**<br>**funds**<br>**Inter-fund**<br>**Transfers**<br>**At 31.03.2026**<br>6,086,<br>49<br>(1,052,692)<br>5,03<br>,<br>57<br>6,086,<br>49<br>(1,052,692)<br>5,03<br>,<br>57<br>-<br>-|
|---|---|



Net movement in funds, included in the above are as follows: 

|General Fund<br>**TOTAL FUNDS**<br>**MOVEMENT**|**Incoming**<br>**resources**<br>**Resources**<br>**expended**<br>**Gains and**<br>**Losses**<br>**Movement in**<br>**funds**<br>651,187<br>(1,481,689)<br>(222,190)<br>(1,052,692)<br>651,187<br>(1,481,689)<br>(222,190)<br>(1,052,692)|
|---|---|



65 



## **HUMANE RESEARCH TRUST CIO (INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

**NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **16. MOVEMENT IN FUNDS - continued** 

## **Comparatives for movement in funds** 

|**Unrestricted**<br>**Funds**<br>General Fund<br>**Restricted Funds**<br>Property Reserve<br>**TOTAL FUNDS**|**At 01.04.2024**<br>**Net**<br>**Movement in**<br>**funds**<br>**Inter-fund**<br>**Transfers**<br>**At 31.03.2025**<br>5,294,<br>67<br>792,082<br>-<br>6,086,<br>49<br>-<br>-<br>-<br>-<br>5,294,367<br>792,082<br>-<br>6,086,449|
|---|---|



Net movement in funds, included in the above are as follows: 

|General Fund<br>Property Reserve<br>**TOTAL FUNDS**<br>**MOVEMENT**|**Incoming**<br>**resources**<br>**Resources**<br>**expended**<br>**Gains and**<br>**Losses**<br>**Movement in**<br>**funds**<br>1,898,151<br>(1,018,5<br>2)<br>(87,527)<br>792,082<br>-<br>-<br>-<br>-<br>1,898,151<br>(1,018,542)<br>(87,527)<br>792,082|
|---|---|



## 17. **CONTINGENT LIABILITIES** 

At 31 March 2026 the Trust had agreed to make future grants of £2,338,596 dependant on certain conditions being met by the claimants. 

## **Grant Commitments** 

|Brought Forward at 01.04.25<br>New commitments in period<br>Grants paid and incurred in period (note 7)<br>Commitments revoked in period<br>Carried Forward at 31.03.26|**£**<br>2,993,396<br>692,769<br>(1,159,797)<br>(187,772)<br>2,338,596|
|---|---|



New commitments in period include requests for top-ups to existing grants approved by the Trust. 

## 18. **RELATED PARTY DISCLOSURES** 

Professor Julie Gough (a trustee) is principal investigator on a grant awarded to University of Manchester and received £79,174 (2025: £72,135) in grant funding in the period. The total value of the grant awarded is £226,008. 

66 



## **HUMANE RESEARCH TRUST CIO** 

## **(INCORPORATING THE LAWSON TAIT MEDICAL AND SCIENTIFIC RESEARCH TRUST)** 

**NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2025 TO 31 MARCH 2026** 

## **19. CONTINGENT ASSETS** 

At 31 March 2026, the Trust had been notified, by executors acting for the estates of 21 deceased supporters of the Trust, of indicative amounts of legacies totalling some £556,650, of which aside from one pecuniary legacies amounting to £1,000 are all residual shares. At 31 March 2026, each estate was at a varying stage of completion and neither the final estate accounts nor schedules of interim distributions had been submitted for approval by the residuary legatees 

67 

